The CAR-TCR Summit is the only dedicated, end-to-end summit focused on accelerating to market the next generation of potent and efficacious CAR-TCR therapies for solid tumor indications, whilst ensuring the accessibility and commercial delivery of current life-changing CAR-TCR therapies to patients around the world.
With two CD19 approved drugs and the space getting increasingly crowded, this year’s CAR-TCR Summit will leverage the experience from those leaders first to market, whilst unveiling the next generation technologies and breakthroughs being developed to enhance CAR-TCR efficacy in solid tumor indications.
You will leave the leading industry dedicated end-to-end summit with clear tangible actions to implement into your strategy and pipeline to deliver “curative” therapies to patients in need.
"I can't speak highly enough about this conference. This conference allowed me to keep informed of the latest research and development on T cell therapies. I was also able to network with some of the leaders in T cell immunotherapies from both academia and the industry."
-Arnab Ghosh, Hematology & Medical Oncology Fellow, MSKCC, CAR-TCR Summit 2017 attendee